April 2026 in “International Journal of Dermatology” This review explores the potential links between PRP treatments for hair loss and scalp skin cancer risk, finding current evidence supports PRP's safety but emphasizes the need for further studies and routine monitoring.
3 citations
,
December 2016 in “Journal of epidemiological research” In this study, only European-ancestry females showed a linear increase in cutaneous malignant melanoma risk with age, potentially due to the loss of HPV-infected androgenic follicles after menopause.
April 2026 in “IntechOpen eBooks” This study reviews the complexities of burn-related skin complications, highlighting postburn pruritus, dyspigmentation, and the risk of malignant ulcers, while offering a framework for evidence-based management through various treatment approaches.
June 2025 in “British Journal of Dermatology” This study found that an ML model incorporating factors like Breslow thickness and age improved cutaneous malignant melanoma prognosis predictions compared to TNM staging, with a C-index of 80% versus 66.6% for TNM alone, suggesting ML's potential for personalized prognostication.
July 2024 in “Journal of Investigative Dermatology” Patients with cutaneous lupus erythematosus have a higher risk of skin cancer and other cancers.
31 citations
,
March 2014 in “Journal of the European Academy of Dermatology and Venereology” In this study, multiple cutaneous adverse effects were observed in patients with metastatic malignant melanoma receiving BRAF inhibitors, but most were well managed with appropriate treatment.
56 citations
,
January 2004 in “Dermatology” This study found that 87% of patients with stage IIA and IIB melanoma treated with low-dose alpha-interferon reported cutaneous side effects, with the most common being hair loss.
This article reviews the cutaneous side effects of immune checkpoint inhibitors and targeted therapies for skin cancers, noting that while generally mild, these effects can influence treatment decisions and quality of life, underscoring the need for physicians to be aware of these adverse reactions.
April 2024 in “JEADV Clinical Practice” This study suggests that establishing international consensus guidelines for including concealed or sensitive sites in routine forensic examinations is crucial to clarify clinician responsibilities, guide patient expectations, and reduce potential medicolegal issues.
10 citations
,
January 2012 in “Journal of Oncology” This paper explores the relationship between the dermal extracellular matrix and cutaneous malignant melanoma, suggesting that ECM involvement may play a key role in the cancer's growth, invasiveness, and initial metastasis.
25 citations
,
May 2018 in “Clinical & Translational Oncology” This review summarizes common skin-related side effects of BRAF inhibitors and immunotherapy in advanced melanoma treatment, reporting no new clinical findings, and emphasizes consensus management to improve patient outcomes.
16 citations
,
February 2019 in “Pediatric Blood & Cancer” In this study, 96% of children with CNS tumors receiving MAPK and mTOR inhibitors experienced common, treatable skin reactions, occasionally requiring therapy adjustments.
6 citations
,
September 2013 in “Journal of Evolution of Medical and Dental Sciences” This study observed a wide range of mucocutaneous disorders among HIV-infected individuals in India, with a significant association between low CD4 cell counts and the presence of infectious and inflammatory skin conditions.
9 citations
,
February 2011 in “Biologics: Targets & Therapy” This review discusses topical calcineurin inhibitors for cutaneous lupus erythematosus and reports no new clinical findings; the authors emphasize the need for more comparative studies with corticosteroids.
7 citations
,
October 2019 in “Annals of palliative medicine” This review examines the incidence and management of dermatologic adverse effects from FDA-approved oral targeted cancer therapies, highlighting frequent occurrences like rashes and rarer severe conditions such as Stevens-Johnson Syndrome.
February 2024 in “Journal of the American Academy of Dermatology” Vascular patterns in dermoscopy help tell apart malignant and benign skin tumors.
October 2023 in “Research Review” This source describes the development, structure, and types of skin appendage tumors, noting both benign and malignant forms, potential associations with syndromes, and categories based on follicular differentiation.
October 2021 in “Nepal journal of dermatology, venereology & leprology” This review discusses the diverse roles and potential skin health benefits of melatonin, highlighting its anti-inflammatory, antioxidant, and protective effects but reports no new clinical results.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
October 2020 in “Our Dermatology Online” This report presents two cases where dermatologists identified internal malignancies—small cell lung cancer and stage IIB cervical cancer—through paraneoplastic skin manifestations.
60 citations
,
May 2015 in “Archives of dermatological research” This review discusses the role of peroxisome proliferator-activated receptors and their agonists in dermatology but reports no new clinical results.
13 citations
,
September 2019 in “Clinical, Cosmetic and Investigational Dermatology” This review discusses the complex nature of erosive pustular dermatosis of the scalp, highlighting the challenges in diagnosis and management, and reports no new clinical findings.
8 citations
,
January 2019 in “JAAD Case Reports” This article describes erosive pustular dermatosis of the scalp, emphasizing its chronic nature, potential complications, and the lack of specific diagnostic findings, but reports no new clinical results.
August 2018 in “Journal of The American Academy of Dermatology” A 90-year-old woman's hand lesion was a rare, aggressive skin cancer treated successfully with surgery.
60 citations
,
September 2013 in “Alimentary Pharmacology & Therapeutics” This review discusses the dermatological adverse events from immunosuppressive and anti-TNF therapy in IBD, finding increased risks of non-melanoma skin cancer and other skin conditions, and recommends regular cancer screening.
46 citations
,
July 2022 in “Frontiers in Oncology” This review discusses recent advancements in cold atmospheric plasma therapies for dermatology, covering optimization, treatment of skin diseases, safety, and does not report new clinical outcomes; it calls for continued research in the field.
39 citations
,
March 2009 in “Dermatology Online Journal” This review observes that trichomegaly, a newly described side effect of EGFR inhibitors causing excessive eyelash and scalp hair growth, persists in some patients whose tumors respond positively to the therapy.
2 citations
,
September 2010 in “Journal of the Dermatology Nurses’ Association” This article provides a detailed analysis of immunosuppressive medications in transplant patients and discusses the increased risk of skin cancer, but it reports no new experimental results.
November 2013 in “International Journal of Dermatology” New skin lesions on the scrotum or vulva in patients with a history of internal cancer could indicate rare skin metastasis.
62 citations
,
April 2009 in “British Journal of Dermatology” This review discusses the potential markers for identifying and studying stem cells in the epidermis and hair follicles, highlighting their role in understanding skin disease pathogenesis and expanding therapeutic options, but reports no new findings.